With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance. However, treating patients with RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the depth and durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.

Owing to this, the 6th Annual RAS-Targeted Drug Development Summit returns as the central hub dedicated to every aspect of discovery and development of RAS, from discovery and clinical development through to commercialization, equipping 200+ global RAS leaders with the means to create effective frontline RAS therapies for better patient outcomes.

Event Link here.